Increased consumption of antithrombin III in patients receiving granulocyte-macrophage colony-stimulating factor after bone marrow transplantation.
Nürnberger
W
W
Michelmann
I
I
Gehentges
S
S
Burdach
S
S
Göbel
U
U
D000990:Antithrombin III / Q000378:metabolism*; D001777:Blood Coagulation / Q000187:drug effects*; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D001779:Blood Coagulation Factors / Q000378:metabolism; D016026:Bone Marrow Transplantation; D006085:Graft Survival / Q000187:drug effects; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D001779:Blood Coagulation Factors; D014409:Tumor Necrosis Factor-alpha; C045072:macrophage procoagulant activity; D016179:Granulocyte Colony-Stimulating Factor; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000990:Antithrombin III